A monoallelic variant in CCN2 causes an autosomal dominant spondyloepimetaphyseal dysplasia with low bone mass

Abstract

Cellular communication network factor 2 (CCN2) is a secreted extracellular matrix-associated protein, and its aberrantly increased expression has been implicated in a diversity of diseases involving pathological processes of fibrosis, chronic inflammation, or tissue injury, which has promoted the evaluation of CCN2 as therapeutic targets for multiple disorders. However, human phenotypes associated with CCN2 deficiency have remained enigmatic; variants in CCN2 have not yet been associated with a human phenotype. Here, we collected families diagnosed with spondyloepimetaphyseal dysplasia (SEMD), and screened candidate pathogenic genes for families without known genetic causes using next-generation sequencing. We identified a monoallelic variant in signal peptide of CCN2 (NM_001901.2: c.65 G > C [p.Arg22Pro]) as the cause of SEMD in 14 subjects presenting with different degree of short stature, premature osteoarthritis, and osteoporosis. Affected subjects showed decreased serum CCN2 levels. Cell lines harboring the variant displayed decreased amount of CCN2 proteins in culture medium and an increased intracellular retention, indicating impaired protein secretion. And the variant weakened the stimulation effect of CCN2 on osteogenesis of bone marrow mesenchymal stem cells. Zebrafish ccn2a knockout model and osteoblast lineage-specific Ccn2-deficient mice (Ccn2^fl/fl;Prx1^Cre) partially recapitulated the phenotypes including low bone mass observed in affected subjects. Pathological mechanism implicated in the skeletal abnormality in Ccn2^fl/fl;Prx1^Cre mice involved decreased bone formation, increased bone resorption, and abnormal growth plate formation. Collectively, our study indicate that monoallelic variants in CCN2 lead to a human inherited skeletal dysplasia, and highlight the critical role of CCN2 in osteogenesis in human.

References

[1.] UngerS, et al. . Nosology of genetic skeletal disorders: 2023 revision. Am. J. Med. Genet. A., 2023, 191: 1164-1209

[2.] Cormier-DaireV. Spondylo-epi-metaphyseal dysplasia. Best Pract. Res. Clin. Rheumatol., 2008, 22: 33-44

[3.] TillerGE, et al. . Dominant mutations in the type II collagen gene, COL2A1, produce spondyloepimetaphyseal dysplasia, Strudwick type. Nat. Genet., 1995, 11: 87-89

[4.] TompsonSW, et al. . A recessive skeletal dysplasia, SEMD aggrecan type, results from a missense mutation affecting the C-type lectin domain of aggrecan. Am. J. Hum. Genet., 2009, 84: 72-79

[5.] ChapmanKL, et al. . Mutations in the region encoding the von Willebrand factor A domain of matrilin-3 are associated with multiple epiphyseal dysplasia. Nat. Genet., 2001, 28: 393-396

[6.] Kennedy, A. M. et al. MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMD(MO). J. Clin. Invest.115, 2832–2842 (2005).

[7.] BargalR, et al. . Mutations in DDR2 gene cause SMED with short limbs and abnormal calcifications. Am. J. Hum. Genet., 2009, 84: 80-84

[8.] Egunsola, A. T. et al. Loss of DDRGK1 modulates SOX9 ubiquitination in spondyloepimetaphyseal dysplasia. J. Clin. Invest.127, 1475–1484 (2017).

[9.] ChoSY, et al. . BGN mutations in X-linked spondyloepimetaphyseal dysplasia. Am. J. Hum. Genet., 2016, 98: 1243-1248

[10.] BatemanJF, Boot-HandfordRP, LamandeSR. Genetic diseases of connective tissues: cellular and extracellular effects of ECM mutations. Nat. Rev. Genet., 2009, 10: 173-183

[11.] KrishnanY, GrodzinskyAJ. Cartilage diseases. Matrix Biol., 2018, 71–72: 51-69

[12.] Murphy-UllrichJE, SageEH. Revisiting the matricellular concept. Matrix Biol., 2014, 37: 1-14

[13.] GiustiV, ScotlandiK. CCN proteins in the musculoskeletal system: current understanding and challenges in physiology and pathology. J. Cell. Commun. Signal., 2021, 15: 545-566

[14.] FuM, PengD, LanT, WeiY, WeiX. Multifunctional regulatory protein connective tissue growth factor (CTGF): a potential therapeutic target for diverse diseases. Acta Pharm. Sin. B., 2022, 12: 1740-1760

[15.] SonnylalS, et al. . Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum., 2010, 62: 1523-1532

[16.] BrigstockDR. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J. Cell. Commun. Signal., 2010, 4: 1-4

[17.] RamazaniY, et al. . Connective tissue growth factor (CTGF) from basics to clinics. Matrix Biol., 2018, 68–69: 44-66

[18.] JunJI, LauLF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat. Rev. Drug. Discov., 2011, 10: 945-963

[19.] KubotaS, TakigawaM. Cellular and molecular actions of CCN2/CTGF and its role under physiological and pathological conditions. Clin. Sci., 2015, 128: 181-196

[20.] AdlerSG, et al. . Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin. J. Am. Soc. Nephrol., 2010, 5: 1420-1428

[21.] RaghuG, et al. . FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. Eur. Respir. J., 2016, 47: 1481-1491

[22.] RicheldiL, et al. . Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir. Med., 2020, 8: 25-33

[23.] ShenYW, ZhouYD, LuanX, ZhangWD. Blocking CTGF-mediated tumor-stroma interplay in pancreatic cancer. Trends Mol. Med., 2020, 26: 1064-1067

[24.] MokalledMH, et al. . Injury-induced ctgfa directs glial bridging and spinal cord regeneration in zebrafish. Science, 2016, 354: 630-634

[25.] YangXG, et al. . Study on weight and height of the Chinese people and the differences between 1992 and 2002. Zhonghua. Liu. Xing. Bing. Xue. Za. Zhi., 2005, 26: 489-493

[26.] LiH, JiC, ZongX, ZhangY. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years. Zhonghua. Er. Ke. Za. Zhi., 2009, 47: 487-492

[27.] ZengQ, et al. . The prevalence of osteoporosis in China, a Nationwide, Multicenter DXA Survey. J. Bone Miner. Res., 2019, 34: 1789-1797

[28.] DietrichK, et al. . Skeletal biology and disease modeling in Zebrafish. J. Bone Miner. Res., 2021, 36: 436-458

[29.] KwonRY, WatsonCJ, KarasikD. Using zebrafish to study skeletal genomics. Bone, 2019, 126: 37-50

[30.] DuSJ, FrenkelV, KindschiG, ZoharY. Visualizing normal and defective bone development in zebrafish embryos using the fluorescent chromophore calcein. Dev. Biol., 2001, 238: 239-246

[31.] LoganM, et al. . Expression of Cre recombinase in the developing mouse limb bud driven by a Prxl enhancer. Genesis., 2002, 33: 77-80

[32.] OwjiH, et al. . A comprehensive review of signal peptides: structure, roles, and applications. Eur. J. Cell. Biol., 2018, 97: 422-441

[33.] Gutierrez GuarnizoSA, et al. . Pathogenic signal peptide variants in the human genome. NAR Genom. Bioinform., 2023, 5

[34.] DonnarummaM, et al. . Molecular analysis and characterization of nine novel CTSK mutations in twelve patients affected by pycnodysostosis. Hum. Mutat., 2007, 28: 524

[35.] FujitaY, et al. . Novel mutations of the cathepsin K gene in patients with pycnodysostosis and their characterization. J. Clin. Endocrinol. Metab., 2000, 85: 425-431

[36.] SunthornthepvarakulT, ChuresigaewS, NgowngarmratanaS. A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J. Clin. Endocrinol. Metab., 1999, 84: 3792-3796

[37.] ChanD, HoMS, CheahKS. Aberrant signal peptide cleavage of collagen X in Schmid metaphyseal chondrodysplasia. Implications for the molecular basis of the disease. J. Biol. Chem., 2001, 276: 7992-7997

[38.] TikhonovaEB, KaramyshevaZN, von HeijneG, KaramyshevAL. Silencing of aberrant secretory protein expression by disease-associated mutations. J. Mol. Biol., 2019, 431: 2567-2580

[39.] LeguitRJ, RaymakersRAP, HebedaKM, GoldschmedingR. CCN2 (Cellular Communication Network factor 2) in the bone marrow microenvironment, normal and malignant hematopoiesis. J. Cell. Commun. Signal., 2021, 15: 25-56

[40.] Abd El KaderT, et al. . The regenerative effects of CCN2 independent modules on chondrocytes in vitro and osteoarthritis models in vivo. Bone, 2014, 59: 180-188

[41.] FriedrichsenS, et al. . CTGF expression during mouse embryonic development. Cell. Tissue Res., 2003, 312: 175-188

[42.] SafadiFF, et al. . Expression of connective tissue growth factor in bone: its role in osteoblast proliferation and differentiation in vitro and bone formation in vivo. J. Cell. Physiol., 2003, 196: 51-62

[43.] Smerdel-RamoyaA, ZanottiS, DeregowskiV, CanalisE. Connective tissue growth factor enhances osteoblastogenesis in vitro. J. Biol. Chem., 2008, 283: 22690-22699

[44.] BattulaVL, et al. . Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment. Blood, 2013, 122: 357-366

[45.] Willems, B. et al. The Wnt co-receptor Lrp5 is required for cranial neural crest cell migration in Zebrafish. PLoS. One10, e0131768 (2015).

[46.] SalhotraA, ShahHN, LeviB, LongakerMT. Mechanisms of bone development and repair. Nat. Rev. Mol. Cell. Biol., 2020, 21: 696-711

[47.] CanalisE, ZanottiS, BeamerWG, EconomidesAN, Smerdel-RamoyaA. Connective tissue growth factor is required for skeletal development and postnatal skeletal homeostasis in male mice. Endocrinology, 2010, 151: 3490-3501

[48.] DirckxN, MoorerMC, ClemensTL, RiddleRC. The role of osteoblasts in energy homeostasis. Nat. Rev. Endocrinol., 2019, 15: 651-665

[49.] IvkovicS, et al. . Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development, 2003, 130: 2779-2791

[50.] KimSM, YuenT, IqbalJ, RubinMR, ZaidiM. The NO-cGMP-PKG pathway in skeletal remodeling. Ann. N. Y. Acad. Sci., 2021, 1487: 21-30

[51.] GaoS, et al. . PI3K-Akt signaling regulates BMP2-induced osteogenic differentiation of mesenchymal stem cells (MSCs): a transcriptomic landscape analysis. Stem. Cell. Res., 2023, 66: 103010

[52.] DongJ, XuX, ZhangQ, YuanZ, TanB. The PI3K/AKT pathway promotes fracture healing through its crosstalk with Wnt/β-catenin. Exp. Cell. Res., 2020, 394: 112137

[53.] SunK, et al. . The PI3K/AKT/mTOR signaling pathway in osteoarthritis: a narrative review. Osteoarthr. Cartil., 2020, 28: 400-409

[54.] Alcorta-SevillanoN, MacíasI, InfanteA, RodríguezCI. Deciphering the relevance of bone ECM signaling. Cells, 2020, 9: 2630

[55.] KawakiH, et al. . Differential roles of CCN family proteins during osteoblast differentiation: involvement of Smad and MAPK signaling pathways. Bone, 2011, 49: 975-989

[56.] KawakiH, et al. . Cooperative regulation of chondrocyte differentiation by CCN2 and CCN3 shown by a comprehensive analysis of the CCN family proteins in cartilage. J. Bone Miner. Res., 2008, 23: 1751-1764

[57.] HurvitzJR, et al. . Mutations in the CCN gene family member WISP3 cause progressive pseudorheumatoid dysplasia. Nat. Genet., 1999, 23: 94-98

[58.] KutzWE, GongY, WarmanML. WISP3, the gene responsible for the human skeletal disease progressive pseudorheumatoid dysplasia, is not essential for skeletal function in mice. Mol. Cell. Biol., 2005, 25: 414-421

[59.] ElseaSH, LucasRE. The mousetrap: what we can learn when the mouse model does not mimic the human disease. Ilar. J., 2002, 43: 66-79

[60.] PoundP, Ritskes-HoitingaM. Is it possible to overcome issues of external validity in preclinical animal research? Why most animal models are bound to fail. J. Transl. Med., 2018, 16

[61.] ThysenS, LuytenFP, LoriesRJ. Targets, models and challenges in osteoarthritis research. Dis. Model. Mech., 2015, 8: 17-30

[62.] Jänne, P. A. et al. Functional overlap between murine Inpp5b and Ocrll may explain why deficiency of the murine ortholog for OCRL1 does not cause Lowe syndrome in mice. J. Clin. Invest.101, 2042–2053 (1998).

[63.] RabenN, NagarajuK, LeeE, PlotzP. Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene. Neuromuscul. Disord., 2000, 10: 283-291

[64.] OhshimaT, et al. . alpha-Galactosidase a deficient mice: a model of Fabry disease. Proc. Natl. Acad. Sci. USA, 1997, 94: 2540-2544

[65.] LeslieND, YagerKL, McNamaraPD, SegalS. A mouse model of galactose-1-phosphate uridyl transferase deficiency. Biochem. Mol. Med., 1996, 59: 7-12

[66.] Westerfield, M. (eds) The Zebrafish Book: A Guide for the Laboratory use of Zebrafish (Oregon Univ. Press, 2000).

[67.] KimmelCB, BallardWW, KimmelSR, UllmannB, SchillingTF. Stages of embryonic development of the zebrafish. Dev. Dyn., 1995, 203: 253-310

[68.] NaseviciusA, EkkerSC. Effective targeted gene ‘knockdown’ in zebrafish. Nat. Genet., 2000, 26: 216-220

Funding

the National Key Research and Development Program of China (2018YFA0800801), the National Basic Research Program of China (2014CB942903), Shanghai Research Center for Endocrine and Metabolic Diseases (2022ZZ01002)